14-day Premium Trial Subscription Try For FreeTry Free
Date Action Amount Person Type
Apr 28, 2024 Sell 2 340 Pulik Richard Common Shares
Apr 24, 2024 Buy 1 261 Fitzgerald Meghan Common Shares
Apr 24, 2024 Sell 83 Fitzgerald Meghan Common Shares
Apr 24, 2024 Buy 1 490 Momtazee James C Common Shares
Apr 24, 2024 Sell 293 Momtazee James C Common Shares
Apr 24, 2024 Buy 2 121 Oren Ilan Common Shares
Apr 24, 2024 Sell 54 Oren Ilan Common Shares
Apr 24, 2024 Buy 1 146 Epperly Melissa B, Common Shares
Apr 24, 2024 Sell 123 Epperly Melissa B, Common Shares
Apr 22, 2024 Buy 230 548 Kumar Rakhi Stock Option (Right to Buy)
Apr 22, 2024 Sell 38 685 Kumar Rakhi Common Shares
Apr 22, 2024 Buy 302 594 Pulik Richard Stock Option (Right to Buy)
Apr 22, 2024 Buy 38 685 Pulik Richard Common Shares
Apr 20, 2024 Sell 10 945 Gline Matthew Common Shares
Apr 20, 2024 Sell 8 515 Pulik Richard Common Shares
Apr 20, 2024 Sell 9 881 Kumar Rakhi Common Shares
Apr 20, 2024 Sell 16 002 Venker Eric Common Shares
Apr 02, 2024 Buy 0 Ramaswamy Vivek Common Shares
Apr 02, 2024 Buy 21 856 138 Ramaswamy Vivek Stock Option (Right to Buy)
Apr 02, 2024 Buy 1 753 905 Ramaswamy Vivek Stock Option (Right to Buy)
Apr 02, 2024 Buy 5 915 052 Ramaswamy Vivek Stock Option (Right to Buy)
Apr 02, 2024 Buy 11 570 769 Ramaswamy Vivek Capped Value Appreciation Rights
Mar 30, 2024 Buy 729 081 Sukhatme Mayukh Common Shares
Mar 30, 2024 Sell 366 211 Sukhatme Mayukh Common Shares
Mar 30, 2024 Sell 1 856 163 Sukhatme Mayukh Capped Value Appreciation Rights
Mar 30, 2024 Buy 390 579 Gline Matthew Common Shares
Mar 30, 2024 Sell 215 991 Gline Matthew Common Shares
Mar 30, 2024 Sell 994 373 Gline Matthew Capped Value Appreciation Rights
Mar 28, 2024 Sell 2 341 Pulik Richard Common Shares
Mar 20, 2024 Sell 16 003 Venker Eric Common Shares
Mar 20, 2024 Sell 1 506 Kumar Rakhi Common Shares
Mar 20, 2024 Sell 10 945 Gline Matthew Common Shares
Mar 07, 2024 Sell 11 325 233 Manchester Keith S Common Shares
Mar 07, 2024 Sell 11 077 765 Manchester Keith S Common Shares
Mar 07, 2024 Sell 5 594 064 Manchester Keith S Common Shares
Mar 07, 2024 Sell 2 260 661 Manchester Keith S Common Shares
Mar 07, 2024 Sell 11 325 233 Gold Daniel Allen Common Shares
Mar 07, 2024 Sell 15 518 673 Gold Daniel Allen Common Shares
Mar 07, 2024 Sell 11 077 765 Gold Daniel Allen Common Shares
Mar 07, 2024 Sell 5 594 064 Gold Daniel Allen Common Shares
Mar 07, 2024 Sell 2 260 661 Gold Daniel Allen Common Shares
Mar 07, 2024 Sell 45 361 Gold Daniel Allen Common Shares
Mar 07, 2024 Sell 11 325 233 Qvt Financial Lp Common Shares
Mar 07, 2024 Sell 15 518 673 Qvt Financial Lp Common Shares
Mar 07, 2024 Sell 11 077 765 Qvt Financial Lp Common Shares
Mar 07, 2024 Sell 5 594 064 Qvt Financial Lp Common Shares
Mar 07, 2024 Sell 2 260 661 Qvt Financial Lp Common Shares
Mar 07, 2024 Sell 45 361 Qvt Financial Lp Common Shares
Feb 28, 2024 Sell 1 630 Pulik Richard Common Shares
Feb 20, 2024 Sell 1 508 Kumar Rakhi Common Shares
Feb 20, 2024 Sell 16 002 Venker Eric Common Shares
Feb 20, 2024 Sell 10 945 Gline Matthew Common Shares
Feb 09, 2024 Sell 96 950 Venker Eric Stock Option (Right to Buy)
Feb 09, 2024 Buy 96 950 Venker Eric Common Shares
Feb 09, 2024 Sell 96 950 Venker Eric Common Shares
Jan 28, 2024 Sell 1 896 Pulik Richard Common Shares
Jan 20, 2024 Sell 1 506 Kumar Rakhi Common Shares
Jan 20, 2024 Sell 10 945 Gline Matthew Common Shares
Jan 20, 2024 Sell 12 377 Venker Eric Common Shares
Jan 19, 2024 Buy 1 570 Momtazee James C Common Shares
Jan 19, 2024 Buy 1 328 Fitzgerald Meghan Common Shares
Jan 19, 2024 Buy 1 207 Epperly Melissa B, Common Shares
Jan 19, 2024 Buy 3 366 Oren Ilan Common Shares
Jan 02, 2024 Sell 3 000 000 Ramaswamy Vivek Common Shares
Dec 28, 2023 Sell 1 913 Pulik Richard Common Shares
Dec 27, 2023 Buy 275 227 Ramaswamy Vivek Common Shares
Dec 27, 2023 Sell 133 911 Ramaswamy Vivek Common Shares
Dec 27, 2023 Sell 251 538 Ramaswamy Vivek Capped Value Appreciation Rights
Dec 27, 2023 Sell 611 393 Ramaswamy Vivek Capped Value Appreciation Rights
Dec 27, 2023 Sell 47 351 Gline Matthew Capped Value Appreciation Rights
Dec 27, 2023 Buy 38 453 Gline Matthew Common Shares
Dec 27, 2023 Sell 22 043 Gline Matthew Common Shares
Dec 27, 2023 Sell 85 232 Gline Matthew Capped Value Appreciation Rights
Dec 27, 2023 Buy 71 365 Sukhatme Mayukh Common Shares
Dec 27, 2023 Sell 159 100 Sukhatme Mayukh Capped Value Appreciation Rights
Dec 27, 2023 Sell 28 411 Sukhatme Mayukh Capped Value Appreciation Rights
Dec 27, 2023 Buy 13 Kumar Rakhi Common Shares
Dec 27, 2023 Sell 6 Kumar Rakhi Common Shares
Dec 27, 2023 Sell 1 894 Kumar Rakhi Capped Value Appreciation Rights
Dec 20, 2023 Sell 16 003 Venker Eric Common Shares
Dec 20, 2023 Sell 10 945 Gline Matthew Common Shares
Dec 20, 2023 Sell 1 364 Kumar Rakhi Common Shares
Nov 29, 2023 Sell 2 360 Pulik Richard Common Shares
Nov 22, 2023 Sell 16 549 Venker Eric Common Shares
Nov 22, 2023 Sell 1 415 Kumar Rakhi Common Shares
Nov 22, 2023 Sell 11 318 Gline Matthew Common Shares
Oct 30, 2023 Sell 2 360 Pulik Richard Common Shares
Oct 24, 2023 Sell 18 261 Venker Eric Common Shares
Oct 24, 2023 Sell 12 489 Gline Matthew Common Shares
Oct 24, 2023 Sell 1 563 Kumar Rakhi Common Shares
Oct 17, 2023 Sell 687 Momtazee James C Common Shares
Oct 16, 2023 Buy 2 269 Oren Ilan Common Shares
Oct 16, 2023 Buy 1 226 Epperly Melissa B, Common Shares
Oct 16, 2023 Buy 1 269 Fitzgerald Meghan Common Shares
Oct 04, 2023 Sell 153 027 Venker Eric Stock Option (Right to Buy)
Oct 03, 2023 Sell 606 221 Venker Eric Stock Option (Right to Buy)
Oct 03, 2023 Buy 606 221 Venker Eric Common Shares
Oct 02, 2023 Sell 440 752 Venker Eric Stock Option (Right to Buy)
Oct 02, 2023 Buy 440 752 Venker Eric Common Shares
Oct 16, 2022 Buy 1 594 Momtazee James C Common Shares
INSIDER POWER
-47.910
Last 100 transactions
Buy: 44 336 179 | Sell: 131 340 506 (Shares)

Based on the 100 latest insides trades, we have calculated the insider power to be negative at a ratio of -47.910.

In total, the insiders bought 44 336 179 and sold 131 340 506 ROIV shares in the last 100 trades.

Click to get the best stock tips daily for free!

About Roivant Sciences Ltd.

Roivant Sciences Ltd. Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aur... ROIV Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT